Stage IV Ovarian Cancer Clinical Trial
Official title:
Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis
NCT number | NCT02441140 |
Other study ID # | 15-029 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | July 2019 |
Verified date | May 2020 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is studying a possible test which may help doctors diagnose women with ovarian cancer.
Status | Terminated |
Enrollment | 5 |
Est. completion date | July 2019 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female - Age = 18 - Able to give informed consent - Scheduled for surgery at Brigham and Women's Hospital for known or highly suspected Stage III or IV ovarian cancer (i.e. elevated CA-125 with a pelvic mass, ascites, and carcinomatosis) - Post-menopausal or negative urine and/or blood pregnancy test - Measurable disease on preoperative imaging Exclusion Criteria: - Male - Age < 18 - Unable to give informed consent - Not planned for surgical intervention - Active malignancy other than ovarian cancer - Prior bilateral tubal ligation or hysterectomy (as this would prevent chromopertubation) - Known or suspected active pelvic infection - Pregnancy - No measurable disease or suspected Stage I or II ovarian cancer on preoperative imaging |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | Celula, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of completed peritoneal fluid collection by culdocentesis after chromopertubation as an assessment of feasibility of peritoneal fluid collection in women with ovarian cancer. | At the time of surgery | ||
Secondary | Measure the concentration of cell free DNA in various biologic fluids and compare it to primary tumor DNA. | At the time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Terminated |
NCT00899093 -
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
|
||
Completed |
NCT00301756 -
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
|
Phase 2 | |
Completed |
NCT00262847 -
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 3 | |
Recruiting |
NCT01000259 -
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
|
N/A | |
Completed |
NCT00066456 -
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Withdrawn |
NCT00551265 -
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
|
N/A | |
Completed |
NCT03188432 -
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT03297489 -
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
|
Early Phase 1 | |
Withdrawn |
NCT00053235 -
Research Study in Patients With Advanced Ovarian Epithelial Cancer
|
N/A | |
Completed |
NCT00194714 -
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
|
Phase 1/Phase 2 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05659381 -
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
|
Phase 3 | |
Terminated |
NCT00003532 -
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01551745 -
Salvage Ovarian FANG™ Vaccine + Bevacizumab
|
Phase 2 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06315270 -
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
|
||
Withdrawn |
NCT02872519 -
PET Imaging of Ovarian Carcinoma With 18F-FSPG
|
Early Phase 1 | |
Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Withdrawn |
NCT02470559 -
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
|
Phase 1 |